CD19 and diffuse large B-cell lymphoma: Of 101 consecutive patients with R/R DLBCL treated with CD19‐targeted CAR T cells during the study period, 7 were excluded because pretreatment PET scans were not available or disease was not measurable, and 1 patient died prior to the first response evaluation (Figure 2).